Viral Vector Gene Therapy: From Discovery to Commercialization
This panel from the 2024 CGT Summit hosted by Charles River Laboratories brings together experts from Moonlight Bio, Ultragenyx, Estellas, UCL, and Charles River to explore the full lifecycle of viral vector gene therapy. The conversation covers critical decisions around plasmid quality, vector selection, and manufacturing scale-up, as well as the challenges of IND-enabling studies, patient enrollment, and navigating global regulatory environments. Panelists also discuss the evolving role of CDMOs, the importance of platform strategies, and how patient advocacy is shaping clinical trial design. Whether you're developing AAV-based therapies or planning for commercialization, this session offers valuable insights into the future of viral vector manufacturing.
https://bit.ly/3KV77dr